person · Reporting owner

SANTINI GINO

Disclosed activity across 8 companies

Tapewire entity: 13210
SEC CIK: 0001276038

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allena Pharmaceuticals, Inc.ALNA · Entity 130904	Director	June 03, 2021	June 04, 2021
COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169	Director	June 08, 2026	June 10, 2026
COMPASS Pathways plcCMPS · Entity 4567	Director	May 27, 2026	May 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allena Pharmaceuticals, Inc.

Report date June 03, 2021 · Filed June 04, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.14 · Expires 2031-06-02	Direct	37,000	Reported balance After 2021-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-03 · Grant · Acquired 37,000 · Balance 37,000 F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Stock option shall vest in full (i.e., in single installment) upon the earlier to occur of the first anniversary of the date of grant or the date of the next annual meeting of stockholders.

COLLEGIUM PHARMACEUTICAL, INC

Report date June 08, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	112,483	Reported balance After 2026-06-08 transaction · row 1 1 source row Row 1 · 2026-06-08 · Exercise / conversion · Acquired 8,700 · Balance 112,483
Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $16.49 · Expires 2026-06-09	Direct	0	Reported balance After 2026-06-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-08 · Exercise / conversion · Disposed 8,700 · Balance 0 F1: The option is fully vested and exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: The option is fully vested and exercisable.

COMPASS Pathways plc

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2036-05-26	Direct	30,158	Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 30,158 · Balance 30,158 F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMAG PHARMACEUTICALS, INC.

Report date November 16, 2020 · Filed November 17, 2020

Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-11-16 transaction · row 1 1 source row Row 1 · 2020-11-16 · Disposition to issuer · Disposed 41,473 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-11-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-16 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-11-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-16 · Disposition to issuer · Disposed 950 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-11-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-16 · Disposition to issuer · Disposed 3,800 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-11-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-16 · Disposition to issuer · Disposed 3,800 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-11-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-16 · Disposition to issuer · Disposed 7,600 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-11-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-16 · Disposition to issuer · Disposed 3,575 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-11-16 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-11-16 · Disposition to issuer · Disposed 12,787 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-11-16 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-11-16 · Disposition to issuer · Disposed 10,110 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-11-16 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-11-16 · Disposition to issuer · Disposed 7,543 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-11-16 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2020-11-16 · Disposition to issuer · Disposed 17,326 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-11-16 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2020-11-16 · Disposition to issuer · Disposed 21,289 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.

F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

ELI LILLY & Co

Report date December 31, 2009 · Filed February 03, 2010

Section 16 reporting ended · disclosed 2010-02-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	96,495	Ending reported balance After 2009-12-07 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2009-05-05 · Gift · Disposed 5,259 · Balance 96,915 Row 2 · 2009-12-07 · Gift · Disposed 420 · Balance 96,495
Common StockSEC Table I · non-derivative	Indirectby daughter	3,806	Reported balance After 2009-05-05 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2009-05-05 · Gift · Acquired 751 · Balance 3,806 F1: Reporting person disclaims beneficial ownership of these shares.
Common StockSEC Table I · non-derivative	Indirectby son	3,806	Reported balance After 2009-05-05 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2009-05-05 · Gift · Acquired 751 · Balance 3,806 F1: Reporting person disclaims beneficial ownership of these shares.
Common StockSEC Table I · non-derivative	Indirectby wife	16,145	Reported balance After 2009-05-05 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2009-05-05 · Gift · Acquired 3,757 · Balance 16,145 F1: Reporting person disclaims beneficial ownership of these shares.
Common StockSEC Table I · non-derivative	Indirect401(k)	3,249	Reported balance Holding disclosure · report date 2009-12-31 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 3,249

Filing footnotes · ownership attribution and instrument terms

F1: Reporting person disclaims beneficial ownership of these shares.

Horizon Therapeutics Public Ltd Co

Report date October 06, 2023 · Filed October 06, 2023

Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2023-10-06 transaction · row 1 1 source row Row 1 · 2023-10-06 · Disposition to issuer · Disposed 100,959 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
Ordinary SharesSEC Table I · non-derivative	IndirectBy Trust	Reported balance After 2023-10-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-10-06 · Disposition to issuer · Disposed 18,655 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.53 · Expires 2025-05-05	Direct	Reported balance After 2023-10-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-10-06 · Disposition to issuer · Disposed 8,548 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.12 · Expires 2027-05-02	Direct	Reported balance After 2023-10-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-10-06 · Disposition to issuer · Disposed 31,153 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 · Expires 2028-05-02	Direct	Reported balance After 2023-10-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-10-06 · Disposition to issuer · Disposed 32,161 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-07-27	Direct	Reported balance After 2023-10-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-10-06 · Disposition to issuer · Disposed 4,016 · Balance 0 F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F6: Reflects the disposition of Issuer's restricted stock unit award (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").

F2: The Option (as defined in footnote 3 to this Form 4) is fully vested.

F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.

F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.

F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024.

F6: Reflects the disposition of Issuer's restricted stock unit award (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration.

INTERCEPT PHARMACEUTICALS, INC.

Report date November 08, 2023 · Filed November 13, 2023

Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-08 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2023-11-08 · Other · Disposed 23,645 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-08 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08	Direct	Reported balance After 2023-11-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82	Direct	Reported balance After 2023-11-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17	Direct	Reported balance After 2023-11-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $183.62	Direct	Reported balance After 2023-11-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-11-08 · Disposition to issuer · Disposed 3,500 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22	Direct	Reported balance After 2023-11-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-11-08 · Disposition to issuer · Disposed 1,598 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01	Direct	Reported balance After 2023-11-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12	Direct	Reported balance After 2023-11-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25	Direct	Reported balance After 2023-11-08 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74	Direct	Reported balance After 2023-11-08 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.

F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.

F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Vitae Pharmaceuticals, Inc

Report date October 25, 2016 · Filed October 25, 2016

Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2024-09-23	Direct	Reported balance After 2016-10-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-10-25 · Disposition to issuer · Disposed 17,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.43 · Expires 2025-05-27	Direct	Reported balance After 2016-10-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.62 · Expires 2026-05-25	Direct	Reported balance After 2016-10-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.

F2: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

F3: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

F4: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 24, 2018 Filed May 29, 2018 21:01 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantCommon Stock	2,253	$0.00	$0.00	Disclosure SEC source: 0001192482-18-000250 · edgar.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,441 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 24, 2019, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date in shares of the issuer's common stock. Read SEC document
May 03, 2018 Filed May 7, 2018 17:06 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantRestricted Stock Units · Derivative	15,320	$0.00	$0.00	Disclosure SEC source: 0001209191-18-028369 · doc4.xml · derivative · entry 5 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,320 Underlying: Ordinary shares · 15,320 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
May 03, 2018 Filed May 7, 2018 17:06 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantStock Option (Right to Buy) · Derivative	32,161	$0.00 Strike: $13.87	$0.00	Disclosure SEC source: 0001209191-18-028369 · doc4.xml · derivative · entry 4 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,161 Underlying: Ordinary shares · 32,161 shares Expires 2028-05-02 F3 · derivative.exercise_date: The option vests in 12 equal monthly installments from the date of grant. Read SEC document
May 03, 2018 Filed May 7, 2018 17:06 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units · Derivative	14,054	$0.00	$0.00	Disclosure SEC source: 0001209191-18-028369 · doc4.xml · derivative · entry 3 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 14,054 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On May 3, 2017, the reporting person was granted 14,054 restricted stock units, vesting in full on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 3, 2017, the reporting person was granted 14,054 restricted stock units, vesting in full on the first anniversary of the grant date. Read SEC document
May 03, 2018 Filed May 7, 2018 17:06 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	5,517	$13.87	$76,520.79	Disclosure SEC source: 0001209191-18-028369 · doc4.xml · nonDerivative · entry 2 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 20,853 Read SEC document
May 03, 2018 Filed May 7, 2018 17:06 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	14,054	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-028369 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 26,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
June 27, 2017 Filed Jun 30, 2017 01:03 UTC	INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343	GrantOption to Purchase Common Stock · Derivative	2,036	$0.00 Strike: $122.01	$0.00	Disclosure SEC source: 0001144204-17-035035 · v470076_form4.xml · derivative · entry 2 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036 Underlying: Common Stock · 2,036 shares Expires 2027-06-27 F1 · derivative.exercise_date: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document
June 27, 2017 Filed Jun 30, 2017 01:03 UTC	INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343	GrantCommon Stock	1,423	$0.00	$0.00	Disclosure SEC source: 0001144204-17-035035 · v470076_form4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,927 F1 · shares: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document
May 24, 2017 Filed May 25, 2017 20:44 UTC	COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169	GrantStock Option (Right to Purchase) · Derivative	19,853	$0.00 Strike: $9.33	$0.00	Disclosure SEC source: 0001192482-17-000141 · edgar.xml · derivative · entry 1 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,853 Underlying: Common Stock · 19,853 shares Expires 2027-05-24 F1 · derivative.exercise_date: The option vests and becomes exercisable on May 24, 2018, subject to the director's continued service with the issuer. Read SEC document
May 18, 2017 Filed May 22, 2017 19:08 UTC	AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305	GrantStock Option (Right to Buy) · Derivative	10,110	Not disclosed Strike: $19.25	Not disclosed	Disclosure SEC source: 0001179110-17-007784 · edgar.xml · derivative · entry 2 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,110 Underlying: Common Stock · 10,110 shares Expires 2027-05-18 F2 · price: Not applicable. F3 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders. Read SEC document
May 18, 2017 Filed May 22, 2017 19:08 UTC	AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305	GrantCommon Stock	4,545	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-17-007784 · edgar.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,510 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's annual meeting of stockholders, however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2 · price: Not applicable. Read SEC document
May 03, 2017 Filed May 4, 2017 18:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantRestricted Stock Units · Derivative	14,054	$0.00	$0.00	Disclosure SEC source: 0001209191-17-030119 · doc4.xml · derivative · entry 5 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,054 Underlying: Ordinary shares · 14,054 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
May 03, 2017 Filed May 4, 2017 18:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantStock Option (Right to Buy) · Derivative	31,153	$0.00 Strike: $15.12	$0.00	Disclosure SEC source: 0001209191-17-030119 · doc4.xml · derivative · entry 4 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,153 Underlying: Ordinary shares · 31,153 shares Expires 2027-05-02 F3 · derivative.exercise_date: The option vests in 12 equal monthly installments from the date of grant. Read SEC document
May 03, 2017 Filed May 4, 2017 18:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units · Derivative	13,953	$0.00	$0.00	Disclosure SEC source: 0001209191-17-030119 · doc4.xml · derivative · entry 3 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 13,953 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On May 3, 2016, the reporting person was granted 13,953 restricted stock units, vesting in full on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 3, 2016, the reporting person was granted 13,953 restricted stock units, vesting in full on the first anniversary of the grant date. Read SEC document
May 03, 2017 Filed May 4, 2017 18:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	5,477	$15.12	$82,812.24	Disclosure SEC source: 0001209191-17-030119 · doc4.xml · nonDerivative · entry 2 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 12,316 Read SEC document
May 03, 2017 Filed May 4, 2017 18:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	13,953	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-030119 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 17,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:32 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	$11.38 Strike: $9.62	$113,800.00	Disclosure SEC source: 0001104659-16-151940 · a4.xml · derivative · entry 3 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-05-25 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4 · derivative.exercise_date: This option, which provided for vesting in four equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:32 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	$8.57 Strike: $12.43	$85,700.00	Disclosure SEC source: 0001104659-16-151940 · a4.xml · derivative · entry 2 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-05-27 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3 · derivative.exercise_date: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:32 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerStock Option (Right to Buy) · Derivative	17,000	$13.00 Strike: $8.00	$221,000.00	Disclosure SEC source: 0001104659-16-151940 · a4.xml · derivative · entry 1 SANTINI GINO · CIK 0001276038 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2024-09-23 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2 · derivative.exercise_date: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document
December 07, 2009 Filed Feb 3, 2010 17:27 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	420	$0.00	$0.00	Disclosure SEC source: 0001209191-10-006405 · doc5.xml · nonDerivative · entry 2 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,495 Read SEC document
May 05, 2009 Filed Feb 3, 2010 17:27 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	3,757	$0.00	$0.00	Disclosure SEC source: 0001209191-10-006405 · doc5.xml · nonDerivative · entry 5 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & BD 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 16,145 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
May 05, 2009 Filed Feb 3, 2010 17:27 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	751	$0.00	$0.00	Disclosure SEC source: 0001209191-10-006405 · doc5.xml · nonDerivative · entry 4 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & BD 10b5-1 filing: Not disclosed Ownership: Indirect · by son Disclosed balance after: 3,806 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
May 05, 2009 Filed Feb 3, 2010 17:27 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	751	$0.00	$0.00	Disclosure SEC source: 0001209191-10-006405 · doc5.xml · nonDerivative · entry 3 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & BD 10b5-1 filing: Not disclosed Ownership: Indirect · by daughter Disclosed balance after: 3,806 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
May 05, 2009 Filed Feb 3, 2010 17:27 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	5,259	$0.00	$0.00	Disclosure SEC source: 0001209191-10-006405 · doc5.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,915 Read SEC document
February 02, 2009 Filed Feb 3, 2009 23:06 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	7,348	$36.82	$270,553.36	Disclosure SEC source: 0001209191-09-006297 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,174 Read SEC document
January 27, 2009 Filed Jan 29, 2009 22:54 UTC	ELI LILLY & Co LLY · Entity 2794	GrantRestricted Stock Unit · Derivative	21,781	$0.00	$0.00	Disclosure SEC source: 0001209191-09-005417 · doc4.xml · derivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,781 Underlying: Common Stock · 21,781 shares Expires 2010-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document
December 15, 2008 Filed Feb 12, 2009 16:40 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	343	$0.00	$0.00	Disclosure SEC source: 0001209191-09-008397 · doc5.xml · nonDerivative · entry 2 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,522 Read SEC document
February 11, 2008 Filed Feb 12, 2009 16:40 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	2,548	$0.00	$0.00	Disclosure SEC source: 0001209191-09-008397 · doc5.xml · nonDerivative · entry 3 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & BD 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 12,388 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
February 11, 2008 Filed Feb 12, 2009 16:40 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	2,548	$0.00	$0.00	Disclosure SEC source: 0001209191-09-008397 · doc5.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & BD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,865 Read SEC document
February 01, 2008 Filed Feb 5, 2008 21:10 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	6,302	$51.52	$324,679.04	Disclosure SEC source: 0001209191-08-007737 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,413 Read SEC document
January 25, 2008 Filed Jan 29, 2008 21:21 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	23,510	$50.74	$1,192,897.40	Disclosure SEC source: 0001209191-08-006224 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,715 Read SEC document
December 11, 2007 Filed Feb 12, 2008 16:50 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	235	$0.00	$0.00	Disclosure SEC source: 0001209191-08-009252 · doc5.xml · nonDerivative · entry 4 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,205 Read SEC document
June 05, 2007 Filed Feb 12, 2008 16:50 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	339	$0.00	$0.00	Disclosure SEC source: 0001209191-08-009252 · doc5.xml · nonDerivative · entry 7 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 9,840 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
June 05, 2007 Filed Feb 12, 2008 16:50 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	339	$0.00	$0.00	Disclosure SEC source: 0001209191-08-009252 · doc5.xml · nonDerivative · entry 3 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,440 Read SEC document
June 04, 2007 Filed Feb 12, 2008 16:50 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	848	$0.00	$0.00	Disclosure SEC source: 0001209191-08-009252 · doc5.xml · nonDerivative · entry 6 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 9,501 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
June 04, 2007 Filed Feb 12, 2008 16:50 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	848	$0.00	$0.00	Disclosure SEC source: 0001209191-08-009252 · doc5.xml · nonDerivative · entry 2 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,779 Read SEC document
May 31, 2007 Filed Feb 12, 2008 16:50 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	843	$0.00	$0.00	Disclosure SEC source: 0001209191-08-009252 · doc5.xml · nonDerivative · entry 5 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 8,653 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document
May 31, 2007 Filed Feb 12, 2008 16:50 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	843	$0.00	$0.00	Disclosure SEC source: 0001209191-08-009252 · doc5.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,627 Read SEC document
February 01, 2007 Filed Feb 5, 2007 23:29 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	1,997	$54.12	$108,077.64	Disclosure SEC source: 0001209191-07-007671 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,470 Read SEC document
January 17, 2007 Filed Jan 19, 2007 21:17 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	20,025	$52.86	$1,058,521.50	Disclosure SEC source: 0001209191-07-004378 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,467 Read SEC document
December 22, 2006 Filed Feb 14, 2007 21:18 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	95	$0.00	$0.00	Disclosure SEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 6 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,442 F2 · kind: Charitable gifts. Read SEC document
December 20, 2006 Filed Feb 14, 2007 21:18 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	192	$0.00	$0.00	Disclosure SEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 5 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,537 F2 · kind: Charitable gifts. Read SEC document
June 23, 2006 Filed Jun 27, 2006 19:39 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	1,543	$54.30	$83,784.90	Disclosure SEC source: 0001209191-06-038275 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,487 Read SEC document
June 09, 2006 Filed Feb 14, 2007 21:18 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	2,316	$0.00	$0.00	Disclosure SEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 21 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 7,810 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document
June 09, 2006 Filed Feb 14, 2007 21:18 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	231	$0.00	$0.00	Disclosure SEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 16 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by son Disclosed balance after: 3,055 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document
June 09, 2006 Filed Feb 14, 2007 21:18 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	231	$0.00	$0.00	Disclosure SEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 11 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Indirect · by daughter Disclosed balance after: 3,055 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document
June 09, 2006 Filed Feb 14, 2007 21:18 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	2,778	$0.00	$0.00	Disclosure SEC source: 0001209191-07-010539 · doc5.xml · nonDerivative · entry 4 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,272 F1 · kind: These transactions involved gifts of securities by the reporting person to his wife, daughter, and son, all of whom share the reporting person's household. The reporting person disclaims beneficial ownership of these shares. Read SEC document
February 23, 2006 Filed Feb 24, 2006 19:58 UTC	ELI LILLY & Co LLY · Entity 2794	Exercise / conversionEmployee stock option 10/96 (right to buy) · Derivative	13,110	$0.00 Strike: $34.60	$0.00	Disclosure SEC source: 0001209191-06-013066 · doc4.xml · derivative · entry 7 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,110 shares Expires 2006-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 23, 2006 Filed Feb 24, 2006 19:58 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	9,636	$56.10	$540,579.60	Disclosure SEC source: 0001209191-06-013066 · doc4.xml · nonDerivative · entry 2 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,030 Read SEC document
February 23, 2006 Filed Feb 24, 2006 19:58 UTC	ELI LILLY & Co LLY · Entity 2794	Exercise / conversionCommon Stock	13,110	$34.60	$453,540.45	Disclosure SEC source: 0001209191-06-013066 · doc4.xml · nonDerivative · entry 1 SANTINI GINO · CIK 0001276038 · Sr.VP, Corp. Strategy & Policy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.